Patents by Inventor Joshua I. Park

Joshua I. Park has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-TREM2 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20220177576
    Abstract: In one aspect, antibodies that specifically bind to a human triggering receptor expressed on myeloid cells 2 (TREM2) protein are provided. In some embodiments, the antibody decreases levels of soluble TREM2 (sTREM2). In some embodiments, the antibody enhances TREM2 activity.
    Type: Application
    Filed: September 17, 2021
    Publication date: June 9, 2022
    Inventors: Mark S. Dennis, Zhenyu Gu, Mihalis Kariolis, Cathal Mahon, Kathryn M. Monroe, Joshua I. Park, Rachel Prorok, Adam P. Silverman, Bettina Van Lengerich
  • ANTI-TREM2 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20220119522
    Abstract: In one aspect, antibodies that specifically bind to a human triggering receptor expressed on myeloid cells 2 (TREM2) protein are provided. In some embodiments, the antibody decreases levels of soluble TREM2 (sTREM2). In some embodiments, the antibody enhances TREM2 activity.
    Type: Application
    Filed: August 16, 2021
    Publication date: April 21, 2022
    Applicant: Denali Therapeutics Inc.
    Inventors: Mark S. Dennis, Sherie Duncan, Kathleen Lisaingo, Kathryn M. Monroe, Joshua I. Park, Rachel Prorok, Ju Shi, Ankita Srivastava, Bettina Van Lengerich, Riley Walsh
  • ANTI-TREM2 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20220073609
    Abstract: In one aspect, antibodies that specifically bind to a human triggering receptor expressed on myeloid cells 2 (TREM2) protein are provided. In some embodiments, the antibody decreases levels of soluble TREM2 (sTREM2). In some embodiments, the antibody enhances TREM2 activity.
    Type: Application
    Filed: August 16, 2021
    Publication date: March 10, 2022
    Applicant: Denali Therapeutics Inc.
    Inventors: Mark S. Dennis, Sherie Duncan, Kathleen Lisaingo, Kathryn M. Monroe, Joshua I. Park, Rachel Prorok, Ju Shi, Ankita Srivastava, Bettina Van Lengerich, Riley Walsh
  • Anti-TREM2 antibodies and methods of use thereof
    Patent number: 11124567
    Abstract: In one aspect, antibodies that specifically bind to a human triggering receptor expressed on myeloid cells 2 (TREM2) protein are provided. In some embodiments, the antibody decreases levels of soluble TREM2 (sTREM2). In some embodiments, the antibody enhances TREM2 activity.
    Type: Grant
    Filed: January 15, 2021
    Date of Patent: September 21, 2021
    Assignee: Denali Therapeutics Inc.
    Inventors: Mark S. Dennis, Zhenyu Gu, Mihalis S. Kariolis, Cathal S. Mahon, Kathryn M. Monroe, Joshua I. Park, Rachel Prorok, Adam P. Silverman, Bettina Van Lengerich
  • ANTI-TREM2 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20210214438
    Abstract: In one aspect, antibodies that specifically bind to a human triggering receptor expressed on myeloid cells 2 (TREM2) protein are provided. In some embodiments, the antibody decreases levels of soluble TREM2 (sTREM2). In some embodiments, the antibody enhances TREM2 activity.
    Type: Application
    Filed: January 15, 2021
    Publication date: July 15, 2021
    Applicant: Denali Therapeutics Inc.
    Inventors: Mark S. Dennis, Zhenyu Gu, Mihalis S. Kariolis, Cathal S. Mahon, Kathryn M. Monroe, Joshua I. Park, Rachel Prorok, Adam P. Silverman, Bettina Van Lengerich
  • Thermophilic cellobiohydrolase
    Patent number: 9624482
    Abstract: The present invention provides for a composition comprising a polypeptide comprising a first amino acid sequence having at least 70% identity with the amino acid sequence of Csac GH5 wherein said first amino acid sequence has a thermostable or thermophilic cellobiohydrolase (CBH) or exoglucanase activity.
    Type: Grant
    Filed: September 28, 2010
    Date of Patent: April 18, 2017
    Assignee: Sandia Corporation
    Inventors: Rajat Sapra, Joshua I. Park, Supratim Datta, Blake A. Simmons
  • Novel thermophilic cellobiohydrolase
    Publication number: 20110207182
    Abstract: The present invention provides for a composition comprising a polypeptide comprising a first amino acid sequence having at least 70% identity with the amino acid sequence of Csac GH5 wherein said first amino acid sequence has a thermostable or thermophilic cellobiohydrolase (CBH) or exoglucanase activity.
    Type: Application
    Filed: September 28, 2010
    Publication date: August 25, 2011
    Applicant: SANDIA CORPORATION
    Inventors: Rajat Sapra, Joshua I. Park, Supratim Datta, Blake A. Simmons
  • Extracellular matrix binding chimeric proteins and methods of use thereof
    Patent number: 7723472
    Abstract: The present invention provides chimeric polypeptides comprising a first polypeptide that binds to a component of extracellular matrix and a second polypeptide that provides for a therapeutic effect. The present invention further provides compositions, including pharmaceutical compositions, comprising a subject chimeric polypeptide. A subject chimeric polypeptide is useful in a variety of treatment, diagnostic, and research applications, which are also provided.
    Type: Grant
    Filed: February 28, 2006
    Date of Patent: May 25, 2010
    Assignee: The Regents of the University of California
    Inventors: Francis C. Szoka, Joshua I. Park, Robert Stull